Sign inJoin waitlistJoin the waitlist

RY

Rona Yaeger

Nancy E. Kemeny Endowed Chair · New York Presbyterian Hospital

Credentials: · · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2010–2012
Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2007–2010
Weill Cornell Medical College
2006–2007
Columbia University Medical Center
2003–2006
New York University Grossman School of Medicine
1999–2003

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine · 2017 · 2,750 citations
OncoKB: A Precision Oncology Knowledge Base
JCO Precision Oncology · 2017 · 2,318 citations

AC
Andrea Cercek
57 papers
LS
Leonard Saltz
52 papers
JS
Jinru Shia
51 papers
MW
Martin Weiser
44 papers
NS
Neil Segal
39 papers
JG
Julio Garcia-Aguilar
37 papers · 11 as a fellow
ZS
Zsofia Stadler
37 papers
EV
Efsevia Vakiani
30 papers
Philip Paty
30 papers
JH
Jaclyn Hechtman
29 papers · 1 as a resident
David Solit
28 papers
Jesse Smith
28 papers

Grants

Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-Low Colorectal Cancer.
National Cancer Institute · R01
Contact PI · $1M · Sloan-Kettering Inst Can Research
2025–2030
Neoadjuvant Tucatinib Plus Trastuzumab in HER2-Amplified Locally Advanced Rectal Cancer
National Cancer Institute · R01
PI · $1.2M · Sloan-Kettering Inst Can Research
2024–2029
Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response
National Cancer Institute · R21
Contact PI · $452.5K · Sloan-Kettering Inst Can Research
2025–2027
Exploiting the Distinct Genomics and Signaling of Colorectal Cancers to Effectively Target ERK
National Cancer Institute · R01
Contact PI · $2.5M · Sloan-Kettering Inst Can Research
2018–2024

Clinical trials

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Principal investigator · Not yet recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2026–2029
Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2013–2015